Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

The annual incidence of cardiac sarcoidosis is low, but increased awareness of this inflammatory condition has led to earlier ...

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab ...

A head-to-toe assessment is conducted to evaluate health status, responses to medications and other therapies, and pain or discomfort, which may be affecting the patient's activities of daily living.

The Food and Drug Administration on Thursday approved an Alnylam Pharmaceuticals medicine for a serious heart condition, a decision that should help the biotechnology firm secure its position as one ...

The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest with recent years witnessing several important controversies. One year earlier, in June 2021 ...

Copyright 2025 The Associated Press. All Rights Reserved. An experimental treatment appears to postpone Alzheimer’s symptoms in some people genetically destined to ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study.